The cardiovascular benefit of Lp(a) reduction: not there yet

Eur Heart J. 2020 Nov 21;41(44):4256-4258. doi: 10.1093/eurheartj/ehaa842.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL
  • Humans
  • Lipoprotein(a)*
  • Risk Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • Cholesterol, LDL
  • Lipoprotein(a)
  • alirocumab